Combined curative radiotherapy including HDR brachytherapy and androgen deprivation in localized prostate cancer: A prospective assessment of acute and late treatment toxicity

References

• Johansson JE, Andren O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. Jama 2004; 291: 2713–9
   PubMed Web of Science ®Google Scholar
• D'Amico AV, Whittington R, Kaplan I, Beard C, Jiroutek M, Malkowicz SB, et al. Equivalent biochemical failure-free survival after external beam radiation therapy or radical prostatectomy in patients with a pretreatment prostate specific antigen of >4–20 ng/ml. Int J Radiat Oncol Biol Phys 1997; 37: 1053–8
   PubMed Web of Science ®Google Scholar
• Nilsson S, Norlen BJ, Widmark A. A systematic overview of radiation therapy effects in prostate cancer. Acta Oncol 2004; 43: 316–81
   PubMed Web of Science ®Google Scholar
• Fowler FJ, Jr, Barry MJ, Lu-Yao G, Roman A, Wasson J, Wennberg JE, et al. Patient-reported complications and follow-up treatment after radical prostatectomy. The National Medicare Experience: 1988–1990 (updated June 1993). Urology 1993; 42: 622–9
   PubMed Web of Science ®Google Scholar
• Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson NE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 2002; 347: 790–6
   PubMed Web of Science ®Google Scholar
• Fowler FJ, Jr, Barry MJ, Lu-Yao G, Wasson JH, Bin L, et al. Outcomes of external-beam radiation therapy for prostate cancer: a study of Medicare beneficiaries in three surveillance, epidemiology, and end results areas. J Clin Oncol 1996; 14: 2258–65
   PubMed Web of Science ®Google Scholar
• Bertermann HaB, F. Technik der perinealen interstitiellen Iridium-192-Betstrahlung des Prostatakarzinoms. Verh. Dtsch. Ges. Urol 1986:256–258.
   Google Scholar
• Borghede G, Hedelin H, Holmang S, Johansson KA, Sernbo G, Mercke C, et al. Irradiation of localized prostatic carcinoma with a combination of high dose rate iridium-192 brachytherapy and external beam radiotherapy with three target definitions and dose levels inside the prostate gland. Radiother Oncol 1997; 44: 245–50
   PubMed Web of Science ®Google Scholar
• Dinges S, Deger S, Koswig S, Boehmer D, Schnorr D, Wiegel T, et al. High-dose rate interstitial with external beam irradiation for localized prostate cancer--results of a prospective trial. Radiother Oncol 1998; 48: 197–202
   PubMedGoogle Scholar
• Galalae RM, Kovacs G, Schultze J, Loch T, Rzehak P, Wilhelm R, et al. Long-term outcome after elective irradiation of the pelvic lymphatics and local dose escalation using high-dose-rate brachytherapy for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 2002; 52: 81–90
   PubMed Web of Science ®Google Scholar
• Kovacs G, Galalae R, Loch T, Bertermann H, Kohr P, Schneider R, et al. Prostate preservation by combined external beam and HDR brachytherapy in nodal negative prostate cancer. Strahlenther Onkol 1999; 175 Suppl 2: 87–8
   PubMedGoogle Scholar
• Mate TP, Gottesman JE, Hatton J, Gribble M, Hollebeke L, et al. High dose-rate afterloading 192Iridium prostate brachytherapy: feasibility report. Int J Radiat Oncol Biol Phys 1998; 41: 525–33
   PubMedGoogle Scholar
• Martin T, Hey-Koch S, Strassmann G, Kolotas C, Baltas D, Rogge B, et al. 3D interstitial HDR brachytherapy combined with 3D external beam radiotherapy and androgen deprivation for prostate cancer. Preliminary results. Strahlenther Onkol 2000; 176: 361–7
   PubMedGoogle Scholar
• Martinez AA, Kestin LL, Stromberg JS, Gonzalez JA, Wallace M, Gustafson GS, et al. Interim report of image-guided conformal high-dose-rate brachytherapy for patients with unfavorable prostate cancer: the William Beaumont phase II dose-escalating trial. Int J Radiat Oncol Biol Phys 2000; 47: 343–52
   PubMed Web of Science ®Google Scholar
• Lennernas B, Holmang S, Hedelin H. High-dose rate brachytherapy of prostatic adenocarcinoma in combination with external beam radiotherapy a long-term follow-up of the first 50 patients at one center. Strahlenther Onkol 2002; 178: 537–41
   PubMedGoogle Scholar
• Michalski JM, Purdy JA, Winter K, Roach M, Vijayakumar S, Sandler HM, et al. Preliminary report of toxicity following 3D radiation therapy for prostate cancer on 3DOG/RTOG 9406. Int J Radiat Oncol Biol Phys 2000; 46: 391–402
   PubMed Web of Science ®Google Scholar
• Sandler HM, McLaughlin PW, Ten Haken RK, Addison H, Forman J, Lichter A, et al. Three dimensional conformal radiotherapy for the treatment of prostate cancer: low risk of chronic rectal morbidity observed in a large series of patients. Int J Radiat Oncol Biol Phys 1995; 33: 797–801
   PubMed Web of Science ®Google Scholar
• Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, et al. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 gy). Int J Radiat Oncol Biol Phys 2002; 54: 1036–46
   PubMed Web of Science ®Google Scholar
• Borghede G, Hedelin H, Holmang S, Johansson KA, Aldenborg F, Pettersson S, et al. Combined treatment with temporary short-term high dose rate iridium-192 brachytherapy and external beam radiotherapy for irradiation of localized prostatic carcinoma. Radiother Oncol 1997; 44: 237–44
   PubMed Web of Science ®Google Scholar
• Martinez AA, Gustafson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, et al. Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 2002; 53: 316–27
   PubMedGoogle Scholar
• Vicini FA, Kestin LL, Martinez AA. Use of conformal high-dose rate brachytherapy for management of patients with prostate cancer: optimizing dose escalation. Tech Urol 2000; 6: 135–45
   PubMedGoogle Scholar
• Egawa S, Shimura S, Irie A, Kitano M, Nishiguchi I, Kuwao S, et al. Toxicity and Health-related Quality of Life During and After High Dose Rate Brachytherapy Followed by External Beam Radiotherapy for Prostate Cancer. Jpn J Clin Oncol 2001; 31: 541–547
   PubMed Web of Science ®Google Scholar
• Lawton CA, Won M, Pilepich MV, Asbell SO, Shipley WU, Hanks GE, et al. Long-term treatment sequelae following external beam irradiation for adenocarcinoma of the prostate: analysis of RTOG studies 7506 and 7706. Int J Radiat Oncol Biol Phys 1991; 21: 935–9
   PubMed Web of Science ®Google Scholar
• Partin AW, Mangold LA, Lamm DM, Walsh PC, Epstein JI, Pearson JD, et al. Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. Urology 2001; 58: 843–8
   PubMed Web of Science ®Google Scholar
• Bolla M, Gonzalez D, Warde P, Dubois JB, Mirimanoff RO, Storme G, et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 1997; 337: 295–300
   PubMed Web of Science ®Google Scholar
• Lennernas B, Rikner G, Letocha H, Nilsson S. External beam radiotherapy of localized prostatic adenocarcinoma. Evaluation of conformal therapy, field number and target margins. Acta Oncol 1995; 34: 953–8
   PubMed Web of Science ®Google Scholar
• Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 1999; 43: 1095–101
   PubMed Web of Science ®Google Scholar
• Rubin P, Constine LS, 3rd, Fajardo LF, Phillips TL, Wasserman TH, et al. EORTC Late Effects Working Group. Overview of late effects normal tissues (LENT) scoring system. Radiother Oncol 1995; 35: 9–10
   PubMedGoogle Scholar
• Pavy JJ, Denekamp J, Letschert J, Littbrand B, Mornex F, Bernier J, et al. EORTC Late Effects Working Group. Late effects toxicity scoring: the SOMA scale. Radiother Oncol 1995; 35: 11–5
   PubMed Web of Science ®Google Scholar
• Schultheiss TE, Lee WR, Hunt MA, Hanlon AL, Peter RS, Hanks GE, et al. Late GI and GU complications in the treatment of prostate cancer. Int J Radiat Oncol Biol Phys 1997; 37: 3–11
   PubMed Web of Science ®Google Scholar
• al-Abany M, Helgason AR, Cronqvist AK, Lind B, Mavroidis P, Wersall P, et al. Dose to the anal sphincter region and risk of fecal leakage. Acta Oncol 2004; 43: 117–8
   PubMed Web of Science ®Google Scholar
• Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, et al. Estimation of the incidence of late bladder and rectum complications after high-dose (70–78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 1998; 41: 83–92
   PubMed Web of Science ®Google Scholar
• Fransson P, Bergstrom P, Lofroth PO, Franzen L, Henriksson R, Widmark A, et al. Daily-diary evaluated side effects of dose-escalation radiotherapy of prostate cancer using the stereotactic BeamCath technique. Acta Oncol 2003; 42: 326–33
   PubMed Web of Science ®Google Scholar
• Nguyen LN, Pollack A, Zagars GK. Late effects after radiotherapy for prostate cancer in a randomized dose-response study: results of a self-assessment questionnaire. Urology 1998; 51: 991–7
   PubMed Web of Science ®Google Scholar
• Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 1999; 353: 267–72
   PubMed Web of Science ®Google Scholar
• Syed AM, Puthawala A, Sharma A, Gamie S, Londrc A, Cherlow JM, et al. High-dose-rate brachytherapy in the treatment of carcinoma of the prostate. Cancer Control 2001; 8: 511–21
   PubMedGoogle Scholar
• Teshima T, Hanks GE, Hanlon AL, Peter RS, Schultheiss TE, et al. Rectal bleeding after conformal 3D treatment of prostate cancer: time to occurrence, response to treatment and duration of morbidity. Int J Radiat Oncol Biol Phys 1997; 39: 77–83
   PubMed Web of Science ®Google Scholar
• Incrocci L, Slob AK, Levendag PC. Sexual (dys)function after radiotherapy for prostate cancer: a review. Int J Radiat Oncol Biol Phys 2002; 52: 681–93
   PubMed Web of Science ®Google Scholar
• al-Abany M, Helgason AR, Cronqvist AK, Svensson C, Wersall P, Steineck P, et al. Long-term symptoms after external beam radiation therapy for prostate cancer with three or four fields. Acta Oncol 2002; 41: 532–42
   PubMed Web of Science ®Google Scholar